The standard approach begins with a 0.25 mg subcutaneous injection once weekly, then increases by 0.25 mg every four weeks, progressing through 0.5 mg, 0.75 mg, 1.0 mg, 1.5 mg, and potentially reaching 2.0 mg or 2.4 mg as maintenance doses
The liquid form allows for faster digestion and better bioavailability than capsules or tablets
Available at: Continue reading [22] Zhang, W., Fan, M., Wang, C
In people, we dont have the answer to that question yet, Wellberg said, but in animal research models, there seems to be evidence that GLP-1s are beneficial by themselves, even in the absence of obesity. Some research suggests that GLP-1 drugs may affect the immune system, rather than lowering the risk for specific cancers, Wellberg said
Like all medicines they can cause side effects, most commonly nausea or digestive discomfort when first starting
The microneedle technology, which involves applying an ultra-small 1cm patch to the arm or abdomen, represents an advanced formulation that significantly enhances user convenience over traditional obesity treatments